OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Moon on the FDA Approval of Relatlimab Plus Nivolumab in Metastatic Melanoma

April 13th 2022

Helen Heng-Shan Moon, MD, discusses the FDA approval of relatlimab plus nivolumab in patients with unresectable or metastatic melanoma.

Dr. Edington on the Evolving Treatment Paradigm of Melanoma

April 12th 2022

Howard D. Edington, MD, discusses the evolving treatment paradigm of melanoma.

Dr. Dietrich on Optimizing Treatment Options for Patients in MCL

April 12th 2022

Martin Dietrich, MD, PhD, discusses optimizing treatment options for patients with mantle cell lymphoma.

Dr. Jeyarajah on Aggressive Treatment while Preserving Quality of Life in CRC

April 12th 2022

Rohan Jeyarajah, MD, discusses aggressive treatment while preserving quality of life in patients with colorectal cancer.

Dr. Anderson on Overcoming Suppressive Signals by Engineering T-cells in Ovarian Cancer

April 12th 2022

Kristin G. Anderson, PhD, discusses overcoming suppressive signaling by engineering T-cells in ovarian cancer.

Dr. Champiat on Early Efficacy of SOT101 Plus Pembrolizumab in Solid Tumors

April 12th 2022

Stéphane Champiat MD, PhD, discusses early efficacy seen with the combination of SOT101 and pembrolizumab in solid tumors.

Dr. Facciabene on Radiation Bridging Therapy Prior to CAR T-Cell Therapy in Mice Models

April 12th 2022

Andrea Facciabene, PhD, discusses investigating the use of bridging radiation therapy prior to CAR T-cell therapy in mice models.

Dr. Gulati on the Prevalence of TSC1 and TSC2 Mutations in Solid Tumors

April 12th 2022

Gunsagar Gulati, MD, discusses the prevalence of TSC1 and TSC2 mutations in solid tumors.

Dr. Kopetz on the BEACON CRC Study and Efficacy Response Analysis in mCRC

April 12th 2022

Scott Kopetz, MD, PhD, FACP, discusses the phase 3 BEACON CRC study and the subsequent efficacy response analysis in patients with BRAF V600E–mutant metastatic colorectal cancer.

Dr. Tagawa on the Investigation of 225Ac-J591 and 177Lu-PSMA-I&T in mCRPC

April 12th 2022

Scott T. Tagawa, MD, MS, FACP, discusses the investigation of 225Ac-J591 and 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer in a phase 1/2 trial.

Dr. Elemento on Utilizing Circulating Tumor Cells to Assess Treatment Resistance in mCRPC

April 10th 2022

Olivier Elemento, PhD, discusses utilizing circulating tumor cells to assess treatment resistance in metastatic castration-resistant prostate cancer.

Dr. Dy on the Use of Sotorasib in KRAS G12C–Mutated NSCLC

April 10th 2022

Grace Dy, MD, discusses the use of sotorasib in patients with non–small cell lung cancer with KRAS G12C mutations.

Dr. Gonzalez-Junca on Combining IL-21 and IL-15 in NK-Cell Therapy

April 10th 2022

Alba Gonzalez-Junca, PhD, discusses combining IL-21 and IL-15 cytokines in NK-cell thearpy.

Dr. Davis on the Influence of Racial Constructs and Genetic Ancestry in TNBC

April 10th 2022

Melissa B. Davis, PhD, discusses the influence of racial constructs and genetic ancestry in triple negative breast cancer.

Dr. Larocca on Recent Advancements in R/R Multiple Myeloma

April 6th 2022

Alessandra Larocca, MD, PhD, discusses recent advancements in relapsed/refractory multiple myeloma.

Dr. Larocca on the Management of Difficult-to-Treat Patients in Multiple Myeloma

April 6th 2022

Alessandra Larocca, MD, PhD, discusses the diagnosis and management of difficult-to-treat patients with multiple myeloma.

Dr. Sammons on Findings From the EMERALD Trial in ER+ Advanced or Metastatic Breast Cancer

April 6th 2022

Sarah Sammons, MD, discusses findings from the phase 3 EMERALD trial in estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer.

Dr. Spigel on Potential Advancements in Targeted Therapy in NSCLC

April 5th 2022

David Spigel, MD, discusses potential upcoming developments in targeted therapies for non–small cell lung cancer.

Dr. Herbst on the Evolution of Targeted Therapies in NSCLC

April 5th 2022

Roy S. Herbst, MD, PhD, discusses the evolving treatment landscape of targeted therapies in non–small cell lung cancer.

Dr. Aggarwal on NGS in Molecular Testing in NSCLC

April 5th 2022

Charu Aggarwal, MD, MPH, discusses the optimal use of next-generation sequencing in molecular testing in non–small cell lung cancer.